| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.082 | 0.08 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.08 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.08 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.09 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.091 | 0.09 |